| Literature DB >> 25760297 |
Claire Y J Wenham, Michael McDermott, Philip G Conaghan1.
Abstract
Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification. With a growing understanding that OA involves multiple tissue pathologies including inflammation, many more therapeutic targets have been identified. This review will provide a current overview on the role of biologics in OA, including anti-tumour necrosis factor agents, growth factors and interleukin-1 antagonists.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25760297 DOI: 10.2174/1381612821666150310144940
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116